Founders of Medicaid had reason to fear that a state-run program would have limited ability to address the needs of vulnerable populations, say authors of Health Affairs piece.
Medicaid is often depicted as a tool for giving disadvantaged people access to healthcare, and the ACA enhanced its role even further in the states that have expanded the program. The Medicaid and CHIP Payment and Access Commission (MACPAC) estimates that between 2013 and 2020, Medicaid enrollment increased by 12.4 million in the Medicaid expansion states, which works out to about a 33% increase.
But a thought-provoking piece posted on the Health Affairs blog yesterday puts a different, starker light on the Medicaid program. While acknowledging its role as a safety net program, the authors say Medicaid’s history and politics are “steeped in the structural racism of the U.S.” and that its policies have “failed to resolve racial health disparities.”
“Evidence of this history remains a plain sight today,” they write. “For instance, elderly Black individuals are more likely to end up in nursing homes where Medicaid is the primary payer compared to their White counterparts.”
Their suggestions for improving Medicaid include putting an emphasis on diseases and conditions that disproportionately affect Black Americans, greater financial support for programs that encourage people of color to train to become healthcare professionals (based on evidence that healthcare improves when physicians and patients share the same race), and enforcement of Title VI of the 1964 Civil Rights Act that bans discrimination on the basis of race or national origin.
“Black patients have been fighting a battle for health equity and justice,” they write. “They deserve support in their fight for equitable healthcare, and this must start with policymakers reckoning with the more than 50-year history of failing to protect Black patients from racist policy decisions affecting the Medicaid program.’
The three authors of the piece are LaShyra T. Nolen, a Harvard Medical School student and the first Black woman to become class president there; Adam L. Beckman, also a Harvard Medical School student; and Emma Sandoe, the associate direct of strategy and planning at North Carolina Medicaid.
Here are some of the main points that Nolen, Beckman, and Sandoe make about Medicaid and its relationship to structural racism:
In its 2012 National Federation of Independent Business vs. Sebelius decision, the Supreme Court made ACA Medicaid expansion optional. Of the 12 states that have not expanded Medicaid, seven are in the South (Alabama, Florida, Georgia, Mississippi, North Carolina, South Carolina, Tennessee and Texas) and most of those states have large Black populations.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Leadership Team at The Cigna Group Revamps in Efforts to Drive Growth, Enhance Customer Focus
March 13th 2025David M. Cordani, chairman and CEO of The Cigna Group, expressed that these moves were made to “build upon our strengths for continued growth, enhance our customer focus, and deliver even greater value for those we serve."
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Leadership Team at The Cigna Group Revamps in Efforts to Drive Growth, Enhance Customer Focus
March 13th 2025David M. Cordani, chairman and CEO of The Cigna Group, expressed that these moves were made to “build upon our strengths for continued growth, enhance our customer focus, and deliver even greater value for those we serve."
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
2 Commerce Drive
Cranbury, NJ 08512